Joshua Bomsztyk

Jun 5, 2024 | onlinelibrary.wiley.com | Joshua Bomsztyk |Sriram Ravichandran |Jahanzaib Khwaja |Oliver Cohen

INTRODUCTION Systemic AL amyloidosis is a condition whereby an abnormal free light chain (FLC), produced by an underlying clonal disorder, misfold and form insoluble amyloid fibrils that deposit in multiple organs resulting in progressive organ dysfunction.1 Anti-plasma cell directed therapies are employed to target the amyloid-producing clonal disorder with a view to reducing or eliminating FLC production.

Jan 3, 2024 | onlinelibrary.wiley.com | Ceri Bygrave |Jahanzaib Khwaja |Joshua Bomsztyk |Maria Atta

CONFLICT OF INTEREST STATEMENT JK, JB, MA, CB, AF, SD, SF, JT, PP, GB, CC, OS, RB, RS, AR and SM: nil to declare. MG: honoraria—Janssen, Amgen and Alnylam; travel support—Novartis, Janssen, Takeda, Stemline therapeutics; consultant—Amgen, Sanofi, Celgene, Stemline therapeutics, Janssen; honoraria—Janssen, Amgen, Alnylam. KJ: Advisory Boards—GSK. AW: honoraria—GSK, Alexion, Attralus, Janssen; travel support—Takeda. REFERENCES 1, , , , , , et al.